Nanostring is seeking an experienced, Director of Product Management to establish and drive all aspects of its Next Generation Sequencing (NGS) business. This is an opportunity to work in a dynamic and entrepreneurial environment while playing a leading role in developing a new sequencing platform and driving NanoString's entry into the NGS market. The new platform will utilize NanoString's proprietary enzyme free, amplification free, hybridization-based single molecule sequencing chemistry called Hyb & SeqTM. This chemistry combines fluorescent molecular barcodes with multi-pass low error rate reads to generate highly accurate data. The role will require a high degree of business acumen balanced by technical expertise and leadership skills. The successful candidate will demonstrate a thorough understanding of the market for both current and future NGS technologies.

Responsibilities:

Business & Program Strategy: Take ownership of the NGS program including product strategy, conceptualization and commercialization plans. Work closely with the CEO and executive team in order to insure the program executes to the business plan and aligns with the overall corporate strategy.

Product Strategy: Take overall ownership of the product definition by providing market inputs to the development and cross-organizational teams. Initiate and manage key opinion leader relationships to support both the development and the commercialization of the product

Marketing & Commercialization Strategy: Define the strategy, lead and execute the overall marketing and commercialization plan including the active involvement of key opinion leaders, the execution of beta and early access programs, the global channel strategy, campaigns, collateral and sales tools.

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.